In recent years, the pharmaceutical industry has come under intense scrutiny for its pricing practices, particularly the habit of raising prices on top drugs twice a year. While often justified by pharmaceutical companies as necessary for research and development, these price hikes have significant consequences for patients, healthcare systems, and society. In this blog post, we will explore the impact of these biannual drug price increases and shed light on their broader implications on healthcare access, affordability, and public health.